Literature DB >> 16369294

Frequency of drug-resistant variants of HIV-1 coexistent with wild-type in treatment-naive patients of India.

Naresh Sachdeva1, Shobha Sehgal, Sunil K Arora.   

Abstract

CONTEXT: Over the past few years, reports of emergence and transmission of drug-resistant strains of HIV have increased, especially in western countries. In the context of increased widespread use of zidovudine- and lamivudine-based combinations in India, coupled with the genetic diversity of HIV, it is essential to generate preliminary data on the frequency of zidovudine- and lamivudine-resistant variants of HIV-1 in North India.
OBJECTIVES: In the present study, the authors screened for mutations in the pol gene of HIV-1 associated with resistance to zidovudine and lamivudine in HIV-infected treatment-naive patients from North India. DESIGN AND PATIENTS: The mutations were screened at codons 70 and 215 (conferring resistance to zidovudine) and at codon 184 (conferring resistance to lamivudine) by using a nested amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) approach from the proviral DNA of 60 patients.
RESULTS: Most of the patients showed a mixture of both wild-type and mutant virus. In all but 1 patient, wild-type virus was observed with respect to each codon. Mutant variants were also observed in many patients, especially at codon 70 (48 patients [80%]) and codon 184 (19 patients [31.67%]). In contrast, the frequency of mutation at codon 215 was found to be very low (1 patient [1.67%]).
CONCLUSIONS: In this sample of treatment-naive HIV-1-infected patients in North India, a high proportion of mutant variants harbored mutations in the pol gene at codons- 70 and 184 coexisting with wild-type HIV-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16369294      PMCID: PMC1681660     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  32 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

2.  Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.

Authors:  I Pellegrin; J Izopet; J Reynes; M Denayrolles; B Montes; J L Pellegrin; P Massip; J Puel; H Fleury; M Segondy
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

3.  HIV-1 drug resistance in newly infected individuals.

Authors:  D Boden; A Hurley; L Zhang; Y Cao; Y Guo; E Jones; J Tsay; J Ip; C Farthing; K Limoli; N Parkin; M Markowitz
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

4.  Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.

Authors:  P Kosalaraksa; M F Kavlick; V Maroun; R Le; H Mitsuya
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Transmission of antiretroviral-drug-resistant HIV-1 variants.

Authors:  S Yerly; L Kaiser; E Race; J P Bru; F Clavel; L Perrin
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

6.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

Authors:  B A Larder; P Kellam; S D Kemp
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

7.  HIV-1 pol sequences from India fit distinct subtype pattern.

Authors:  L E Soto-Ramirez; S Tripathy; B Renjifo; M Essex
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-12-01

8.  Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.

Authors:  M A Wainberg; H Salomon; Z Gu; J S Montaner; T P Cooley; R McCaffrey; J Ruedy; H M Hirst; N Cammack; J Cameron
Journal:  AIDS       Date:  1995-04       Impact factor: 4.177

9.  Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.

Authors:  M D de Jong; J Veenstra; N I Stilianakis; R Schuurman; J M Lange; R J de Boer; C A Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

Review 10.  Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Authors:  M S Hirsch; B Conway; R T D'Aquila; V A Johnson; F Brun-Vézinet; B Clotet; L M Demeter; S M Hammer; D M Jacobsen; D R Kuritzkes; C Loveday; J W Mellors; S Vella; D D Richman
Journal:  JAMA       Date:  1998-06-24       Impact factor: 56.272

View more
  4 in total

1.  AIDS in India.

Authors:  S Solomon; S S Solomon; A K Ganesh
Journal:  Postgrad Med J       Date:  2006-09       Impact factor: 2.401

2.  Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.

Authors:  Patrycja Machnowska; Karolin Meixenberger; Daniel Schmidt; Heiko Jessen; Heribert Hillenbrand; Barbara Gunsenheimer-Bartmeyer; Osamah Hamouda; Claudia Kücherer; Norbert Bannert
Journal:  PLoS One       Date:  2019-01-16       Impact factor: 3.240

3.  High producer haplotype (CAG) of -863C/A, -308G/A and -238G/A polymorphisms in the promoter region of TNF-α gene associate with enhanced apoptosis of lymphocytes in HIV-1 subtype C infected individuals from North India.

Authors:  Sukhvinder Singh; Aman Sharma; Sunil K Arora
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

4.  Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults.

Authors:  Mary F Kearney; Jonathan Spindler; Ann Wiegand; Wei Shao; Richard Haubrich; Sharon Riddler; Christina M Lalama; Michael D Hughes; John M Coffin; John W Mellors
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.